News

1 to 9 of 137 results

Brazil and Mexico physicians’ preferences on anticoagulants

25-07-2014

Novel oral anticoagulants (NOACs) such as Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa…

BayerBoehringer IngelheimBrazilBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingMexicoPfizerPharmaceuticalPradaxaPricingXarelto

High price of novel antithrombotics a major deterrent to patient access in China

High price of novel antithrombotics a major deterrent to patient access in China

10-06-2014

The high cost of therapy remains a significant barrier for uptake of novel oral anticoagulants (NOACs)…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularChinaEliquisMarkets & MarketingPharmaceuticalPradaxaPricingWarfarin SodiumXarelto

Novel oral anticoagulants will continue to drive atrial fibrillation drug market growth

20-12-2013

The atrial fibrillation drug market will experience continued growth through the rest of the decade,…

Asia-PacificBayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisEuropeMarkets & MarketingNorth AmericaPfizerPharmaceuticalPradaxaXarelto

First human data show promise of Boehringer’s specific antidote for Pradaxa-induced anticoagulation

First human data show promise of Boehringer’s specific antidote for Pradaxa-induced anticoagulation

19-11-2013

Presented for the first time at the American Heart Association’s (AHA) Scientific Sessions, results…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisPharmaceuticalPradaxaResearchXarelto

EU regulator finds no added pancreatic risks for GLP-1 diabetes drugs

26-07-2013

Having finalized a review of glucagon-like peptide 1 (GLP-1)-based diabetes therapies, the European Medicines…

AstraZenecaBoehringer IngelheimBristol-Myers SquibbBydureonDiabetesEli LillyEuropeJanuviaMerck & CoNovo NordiskOnglyzaPharmaceuticalRegulationTradjentaVictoza

FDA probes possible higher risk of pancreatitis for newer type 2 diabetes drugs

15-03-2013

The US Food and Drug Administration revealed in a web posting yesterday that it is evaluating unpublished…

Boehringer IngelheimBristol-Myers SquibbDiabetesEli LillyExenatide InjectionlinagliptinMerck & CoNorth AmericaNovo NordiskPharmaceuticalRegulationsaxagliptinsitagliptinVictoza

Brazil's atrial fibrillation market expected to grow at 31% pa over next five years

22-01-2013

The Brazilian market for atrial fibrillation will increase at a rate of 31% per year from 2011 to 2016,…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularDaiichi SankyoEliquisLixianaMarkets & MarketingPharmaceuticalPradaxaSouth AmericaXarelto

Brazil's atrial fibrillation market to grow at 31% annually over the next five years

19-12-2012

The Brazilian market for atrial fibrillation will increase at a rate of 31% per year from 2011 to 2016,…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularDaiichi SankyoEliquisLixianaMarkets & MarketingPfizerPharmaceuticalPradaxaPricingSouth AmericaXarelto

1 to 9 of 137 results

Back to top